Relevance of in vitro neurotoxicity testing for regulatory requirements: Challenges to be considered

被引:69
|
作者
Bal-Price, Anna K. [1 ]
Hogberg, Helena T. [1 ]
Buzanska, Leonora [1 ,2 ]
Coecke, Sandra [1 ]
机构
[1] Commiss European Communities, Joint Res Ctr, European Ctr Validat Alternat Methods, Inst Hlth & Consumer Protect,In Vitro Toxicol Uni, I-21020 Ispra, VA, Italy
[2] Polish Acad Sci, Med Res Ctr, NeuroRepair Dept, Warsaw, Poland
关键词
In vitro neurotoxicity testing; Models; Endpoints; Metabolism; New technologies; EMBRYONIC STEM-CELLS; NEURAL PROGENITOR CELLS; UMBILICAL-CORD BLOOD; DEVELOPMENTAL NEUROTOXICITY; NEURITE OUTGROWTH; DIFFERENTIATION; TOXICITY; METABOLISM; LINE; RECOMMENDATIONS;
D O I
10.1016/j.ntt.2008.12.003
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The current testing requirements for both adult and developmental neurotoxicity evaluation are based on in vivo animal models and the neurotoxic potency of compounds is mainly determined by neurobehavioural and neuropathological effects. In vitro studies are considered complementary to animal tests because they provide an understanding of the molecular/cellular mechanisms involved in neurotoxicity. However, the selection of relevant in vitro neuronal/glial specific endpoints applied to various neuronal cellular models should be done in a careful way to build reliable and feasible testing strategies since usually these endpoints have to be tested in various complementary in vitro systems. The requirements for applying a more complex test strategy where toxicokinetic aspects are included together with different tools to compensate for the lack of in vitro metabolic competence are discussed. Taking into consideration the recent European Commission chemical legislation concerning registration, evaluation and authorisation of chemicals (REACH) it has become a priority to develop new intelligent testing strategies integrating computational models and in vitro assays based on cell culture models and endpoints that are amenable for adaptation to high throughput screening to be able to test a large number of chemicals. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:36 / 41
页数:6
相关论文
共 50 条
  • [1] Establishment of in vitro assays for regulatory developmental neurotoxicity testing
    Bartmann, K.
    Masjosthusmann, S.
    Stuerzl, L. -C.
    Waldmann, T.
    Leist, M.
    Fritsche, E.
    TOXICOLOGY LETTERS, 2019, 314 : S221 - S221
  • [2] Proficiency Testing in the Clinical Laboratory: Challenges and Benefits Beyond Regulatory Requirements
    Stang, Heather L.
    Astles, J. Rex
    Breckenridge, Karen
    Willis, Jane
    Thompson, Pamela
    Zavahir, Yasmine
    Anderson, Nancy L.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 138 : A188 - A188
  • [3] Application of in vitro neurotoxicity testing for regulatory purposes:: Symposium III summary and research needs
    Bal-Price, Anna K.
    Sunol, Cristina
    Weiss, Dieter G.
    van Vliet, Erwin
    Westerink, Remco H. S.
    Costa, Lucio G.
    NEUROTOXICOLOGY, 2008, 29 (03) : 520 - 531
  • [4] Noncombustibility: Testing and regulatory requirements
    Hirschler, Marcelo M.
    FIRE AND MATERIALS, 2023, 47 (02) : 182 - 198
  • [5] NEUROTOXICITY TESTING - REGULATORY PERSPECTIVES - EXPERIENCE WITH ACRYLAMIDE
    LOSOS, GJ
    EXPERIMENTAL PATHOLOGY, 1989, 36 (01): : 18 - 19
  • [6] Neurotoxicity testing:: A discussion of in vitro alternatives
    Costa, LG
    ENVIRONMENTAL HEALTH PERSPECTIVES, 1998, 106 : 505 - 510
  • [7] Regulatory Requirements for Stability Testing of Generics
    Buehler, Gary
    Huynh-Ba, Kim
    PHARMACEUTICAL STABILITY TESTING TO SUPPORT GLOBAL MARKETS, 2010, 12 : 61 - +
  • [8] Key challenges for in vitro testing of tobacco products for regulatory applications: Recommendations for dosimetry
    Miller-Holt, Jacqueline
    Behrsing, Holger
    Crooks, Ian
    Curren, Rodger
    Demir, Kubilay
    Gafner, Jeremie
    Gillman, Gene
    Hollings, Michael
    Leverette, Robert
    Oldham, Michael
    Simms, Liam
    Stankowski, Leon F.
    Thorne, David
    Wieczorek, Roman
    Moore, Martha M.
    DRUG TESTING AND ANALYSIS, 2023, 15 (10) : 1175 - 1188
  • [9] The value of alternative testing for neurotoxicity in the context of regulatory needs
    Coecke, S
    Eskes, C
    Gartlon, J
    Kinsner, A
    Price, A
    van Vliet, E
    Prieto, P
    Boveri, M
    Bremer, S
    Adler, S
    Pellizzer, C
    Wendel, A
    Hartung, T
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2006, 21 (02) : 153 - 167
  • [10] An improved approach to regulatory developmental neurotoxicity testing (DNT)
    Vorhees, Charles
    Williams, Michael
    NEUROTOXICOLOGY AND TERATOLOGY, 2018, 67 : 77 - 77